DNA repair and damage pathways in mesothelioma development and therapy

Malakoti, Faezeh; Targhazeh, Niloufar; Abadifard, Erfan; Zarezadeh, Reza; Samemaleki, Sahar; Asemi, Zatollah; Younesi, Simin; Mohammadnejad, Reza; Hossini, Seyed Hadi; Karimian, Ansar; Alemi, Forough; Yousefi, Bahman

doi:10.1186/s12935-022-02597-9

Cited by 9 publications

(6 citation statements)

References 107 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MAPK ERK1/2 pathway is involved in different cellular processes, e.g., survival and apoptosis, proliferation, differentiation and inflammation, and is often activated in many cancers, including mesothelioma, where it plays a key role in asbestos-induced carcinogenesis [ 31 , 41 ]. Previous studies demonstrated that GHRH antagonist JMR-132 inhibits the growth of human prostate cancer xenografted into nude mice through the inactivation of ERK [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma

Gesmundo

Pedrolli

Vitale

et al. 2022

IJMS

View full text Add to dashboard Cite

Pleural mesothelioma (PM) is an aggressive cancer with poor prognosis and no effective therapies, mainly caused by exposure to asbestos. Antagonists of growth hormone-releasing hormone (GHRH) display strong antitumor effects in many experimental cancers, including lung cancer and mesothelioma. Here, we aimed to determine whether GHRH antagonist MIA-690 potentiates the antitumor effect of cisplatin and pemetrexed in PM. In vitro, MIA-690, in combination with cisplatin and pemetrexed, synergistically reduced cell viability, restrained cell proliferation and enhanced apoptosis, compared with drugs alone. In vivo, the same combination resulted in a strong growth inhibition of MSTO-211H xenografts, decreased tumor cell proliferation and increased apoptosis. Mechanistically, MIA-690, particularly with chemotherapeutic drugs, inhibited proliferative and oncogenic pathways, such as MAPK ERK1/2 and cMyc, and downregulated cyclin D1 and B1 mRNAs. Inflammatory pathways such as NF-kB and STAT3 were also reduced, as well as oxidative, angiogenic and tumorigenic markers (iNOS, COX-2, MMP2, MMP9 and HMGB1) and growth factors (VEGF and IGF-1). Overall, these findings strongly suggest that GHRH antagonists of MIA class, such as MIA-690, could increase the efficacy of standard therapy in PM.

show abstract

Section: Discussionmentioning

confidence: 99%

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma

Gesmundo

Pedrolli

Vitale

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The current review shows that the DDR pathway also seems to be involved in PeM, which is in line with literature on mesothelioma. 28 In almost half of the patients with PeM, BAP1 was altered. BAP1 is involved in multiple processes, including DDR, and acts as a TSG by binding to BRCA1 , another well-known TSG.…”

Section: Discussionmentioning

confidence: 99%

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies

Dietz¹,

Kooten²,

Paats

et al. 2023

ESMO Open

View full text Add to dashboard Cite

“…We also identi ed mutations in MET, TP53, CDKN2A/2B, and RB1 in more than one tumor. BAP1 has important functions in tumor suppression [33] and has been reported in various cellular processes, including DNA damage response [34,35] , chromosome stability [36] ,…”

Section: Discussionmentioning

confidence: 99%

The clinical outcome, pathologic spectrum, and genomic landscape of 454 cases of salivary mucoepidermoid carcinoma

Wang¹,

Yan

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives To investigate the clinicopathological and molecular features of salivary mucoepidermoid carcinoma (MEC).Design The clinical features, treatment outcomes, and pathological parameters of 454 MECs were evaluated, and their genomic features were analyzed using whole-exome sequencing and whole-transcriptome sequencing.Results 414 patients were alive without relapse at follow-up, after an average period of 62 months (1–116 months). The disease progressed after initial treatment in 40 patients. The lungs were the most common site of distant metastasis. For classical MECs, histologic gradings of the AFIP, modified Healey, and MSK systems were significantly associated with recurrence and lymph nodal metastasis; these gradings were significantly related to lymph nodal metastasis for the subtypes. Older age, minor salivary gland involvement, clinical symptoms, high TNM stage, high-grade tumor, and improper surgical modality were the main prognostic factors. BAP1 was the most frequently mutated gene in MEC. Mutations in CDKN2A, MET, and TP53 were more frequently found in aggressive tumor phenotypes. MAML2 rearrangement was observed in 42% of patients, and EWSR1 rearrangement in 8%. Specific genetic events (in TP53 and FBXW7) associated with CRTC1–MAML2 fusion might cause MEC progression and might be associated with unfavorable prognosis.Conclusions A complete understanding of the high heterogeneity of MEC in histology and genetics would help in accurate diagnosis and treatment.

show abstract

DNA repair and damage pathways in mesothelioma development and therapy

Cited by 9 publications

References 107 publications

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies

The clinical outcome, pathologic spectrum, and genomic landscape of 454 cases of salivary mucoepidermoid carcinoma

Contact Info

Product

Resources

About